Standorte / Kliniken / Häuser
Unternehmen
Onkologie - Titelbild

Onkologie

(Oncology)

    Research

    Goal

    Our aim is to translate novel molecular imaging and radionuclide therapy applications to achieve improved outcomes in cancer patients.

    Focus on Theranostic

    Major focus is the assessment of theranostic radioligands, i.e. molecules designed to deliver radiation into tumor lesions. Theranostic radioligands/radionuclides enable a combination of accurate detection and efficacious radionuclide therapy. Our research aims to establish new radioligand applications for substantial clinical improvement.

    Clinical projects assess the impact of molecular imaging on tumor detection, clinical stage and outcome. Longitudinal cohort studies examine the efficacy and safety of radionuclide therapy. Projects are carried out in close collaboration with Oncology, Urology and other Clinical Partners.

    Translational projects address among other topics a current NEED for the advancement of theranostic:

    • N ovel cancer targets for radionuclide imaging and therapy
    • E valuation of risk and response
    • E scalation of activity and radiation dose
    • D rug combination therapy

    Funding

    Financial support is provided by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG), Mercator Research Center Ruhr (MERCUR), IFORES, Doktor Robert Pfleger-Stiftung, Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg, Landeskrebsregister NRW, Winterseminar UKE, and SOFIE Bioscience.

    Prof. Dr. med.
    Wolfgang Fendler

    Nuclear Medicine Attending, Vice Chair, Head of Translational Oncology

    Team

    Theranostic Radioligands bind to specific surface proteins of cancer cells. Upon binding Radioligands undergo internalization for radiation delivery.

    Kontakt

    Tel.: 0201 723 2073
    Fax: 0201 723 5964
    Email: sekretariat.nuklearmedizin@uk-essen.de

    Past Milestones for Nuclear Medicine and Oncology in Essen

    Selected Publications

    https://pubmed.ncbi.nlm.nih.gov/?term=Fendler+WP

    • New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. Karpinski M.J. et al. Fendler W.P. Lancet Oncol. 2026
    • Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study Karpinski M.J. et al. Fendler W.P. Eur Urol. 2025 Nov;88(5):484-495.
    • Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. Weber M, Kersting D, …, Fendler WP. Clin Cancer Res. 2022 Oct 3;28(19):4194-4202.
    • Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. Fendler WP, Pabst KM, …, Hamacher R. Clin Cancer Res. 2022 Oct 3;28(19):4346-4353.
    • Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Karpinski MJ, …, Fendler WP. Lancet Oncol. 2024 Jul 29:S1470-2045(24)
    • Prostate-Specific Membrane Antigen Ligand Positron-Emission-Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. WP Fendler, …, B Hadaschik. Clin Cancer Res. 2019 Dec 15;25(24):7448-7454.
    • Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. Fendler WP, …, Hope TA. JAMA Oncol. 2019 Jun 1;5(6):856-863.
    • Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. Fendler WP, …, Herrmann K. J Nucl Med. 2017 Nov;58(11):1786-1792.
    • German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. Rahbar K, …, Fendler WP, Krause BJ. J Nucl Med. 2017 Jan;58(1):85-90.
    • 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. doi: 10.1007/s00259-017-3670-z.
    • EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3.
    • Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Seifert R. et. al. Fendler WP, Eiber M. Eur Urol. 2023 May;83(5):405-412.

    Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.

    Sartor O, Hope TA, Calais J, Fendler WP.

    J Nucl Med. 2021 Feb;62(2):146-148. doi: 10.2967/jnumed.120.261834.

    https://www.promise-pet.org

    Selected Awards

    2021Preis der Dr. Dagobert Nitz-Stiftung, Wolfgang Fendler
    2021European Prostate Cancer Research Award 2021 from the Fritz H. Schröder Foundation, Wolfgang Fendler
    2023Therapy Center of Excellence Award of the Society of Nuclear Medicine and Molecular Imaging, Kim Pabst
    2024Best Young Authors Award EANM24, Madeleine Karpinski
    2024Preis der MRGN 2024, Madeleine Karpinski
    2025Maximilian Nitze-Preis 2025 der Deutschen Gesellschaft für Urologie (DGU), Wolfgang Fendler
    2025Preis der Deutschen Hochschulmedizin 2025 awarded on the annual meeting in Berlin; Project: PROMISE, Team
    2025Heinz-Hundeshagen Preis der DGN, Madeleine Karpinski
    2025Dagmar Eißner Preis, Helena Lanzafame